SCHEMBL5655019

SCHEMBL5655019

CCOC(=O)CCCCCN(C)C(=O)OC(C)(C)C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.44
HDAC2 Q92769 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
DNM1 Q05193 1/20 0.43
CYP1A2 P05177 1/20 0.42
GAA P10253 1/20 0.41
ALDH1A1 P00352 2/20 0.40
ALOX15 P16050 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
CYP3A4 P08684 1/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
USP2 O75604 1/20 0.40
DGKA P23743 1/20 0.39
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
KDM5A P29375 1/20 0.37
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
BCHE P06276 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14822004 0.94 CYP1A2 (0.44) HDAC1HDAC2HDAC6DNM1CYP1A2
SCHEMBL499027 0.87 SMN1; SMN2 (0.40) HDAC1HDAC2HDAC6DNM1CYP1A2
SCHEMBL20117268 0.85 DNM1 (0.44) HDAC1HDAC2HDAC6DNM1TDP1
SCHEMBL19784441 0.85 HDAC1 (0.44) HDAC1HDAC2HDAC6DNM1CYP1A2
SCHEMBL903563 0.84 TSHR (0.44) HDAC1HDAC2HDAC6ALDH1A1TSHR
SCHEMBL17940876 0.83 L3MBTL1 (0.39) HDAC1HDAC2HDAC6DNM1CYP1A2
SCHEMBL9354449 0.83 TSHR (0.45) HDAC1HDAC2HDAC6ALDH1A1TSHR
SCHEMBL10042565 0.81 CA12 (0.40) HDAC1HDAC2HDAC6CYP1A2GAA
SCHEMBL23113130 0.81 EPHX2 (0.45) HDAC1HDAC2HDAC6ALDH1A1ALOX15
SCHEMBL8360181 0.81 EPHX2 (0.45) HDAC1HDAC2HDAC6ALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142638-A1 Ornithine derivatives as prostaglandin e2 agonists or antagonists ASTELLAS PHARMA INC. (JP) 2007-06-21 US disclosed
CN-1898227-A As prostaglandin E2Ornithine derivatives as agonists or antagonists ASTELLAS PHARMA INC (JP) 2007-01-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142638-A1 Ornithine derivatives as prostaglandin e2 agonists or antagonists PTGER4, OXER1, RXFP4 HDAC1 1416/4885HDAC2 815/4885HDAC6 2949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.